What is the translation of " AVASTIN IN COMBINATION " in Slovenian?

• zdravilo avastin v kombinaciji
• zdravilom avastin v kombinaciji

Examples of using Avastin in combination in English and their translations into Slovenian

The efficacy results of Avastin in combination with IFL-chemotherapy are displayed in Table 4.
Rezultate učinkovitosti zdravila Avastin v kombinaciji z IFL-kemoterapijo prikazuje preglednica 4.

Patients who have experienced a venous thromboembolic event may be at higher risk for a recurrence if they receive Avastin in combination with chemotherapy versus chemotherapy alone.
Pri bolnikih, pri katerih se je pojavil venski trombembolični dogodek, obstaja povečano tveganje za ponovitev, če prejemajo zdravilo Avastin v kombinaciji s kemoterapijo kot pa če prejemajo le kemoterapijo.

Avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.
Zdravilo Avastin je v kombinaciji s paklitakselom indicirano za prvo linijo zdravljenja bolnikov z metastatskim rakom dojk.

Table 1 lists adverse drug reactions associated with the use of Avastin in combination with different chemotherapy regimens in multiple indications.
V preglednici 1 so našteti neželeni učinki, ki so povezani z uporabo zdravila Avastin v kombinaciji z različnimi shemami kemoterapije pri več indikacijah.

Avastin in Combination with Interferon alfa-2a for the First-Line Treatment of Advance and/ or Metastatic Renal Cell Cancer(BO17705).
Zdravilo Avastin v kombinaciji z interferonom alfa 2- a v prvi liniji zdravljenja napredovalega in/ ali metastatskega raka ledvičnih celic(BO17705).

Tables 1 and 2 list adverse reactions associated with the use of Avastin in combination with different chemotherapy regimens in multiple indications.
V preglednicah 1 in 2 so našteti neželeni učinki, ki so povezani z uporabo zdravila Avastin v kombinaciji z različnimi shemami kemoterapije pri več indikacijah.

Avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and/ or metastatic renal cell cancer.
Zdravilo Avastin je v kombinaciji z interferonom alfa- 2a indicirano za prvo linijo zdravljenja bolnikov z napredovalim in/ ali metastatskim rakom ledvičnih celic.

The efficacy data from trials AVF0780g and AVF2192g investigating Avastin in combination with 5-FU/FA-chemotherapy are summarised in Table 5.
Podatki o učinkovitosti iz preskušanj AVF0780g in AVF2192g, ki sta proučevali zdravilo Avastin v kombinaciji s kemoterapevtsko shemo 5-FU/FA, so povzeti v preglednici 5.

In these studies, Avastin, in combination with carboplatin and paclitaxel, was compared with carboplatin and paclitaxel alone.
V teh študijah so zdravilo Avastin v kombinaciji s karboplatinom in paklitakselom primerjali s karboplatinom in paklitakselom kot samostojnima zdraviloma..

This was a phase II randomised, active-controlled, open-labelled clinical trial investigating Avastin in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer.
To je bilo randomizirano, aktivno kontrolirano, odprto klinično preskušanje faze II, v katerem so proučevali kombinacijo zdravila Avastin s 5-FU/FA kot prvo linijo zdravljenja metastatskega raka debelega črevesa in danke.

In one clinical trial evaluating Avastin in combination with 5-fluorouracil/folinic acid, AVF2192g, patients with metastatic colorectal cancer who were not candidates for treatment with irinotecan were included.
Bolniki z metastatskim rakom debelega črevesa in danke, ki niso bili primerni za zdravljenje z irinotekanom, so bili vključeni v klinično preskušanje AVF2192g, ki je ocenjevalo zdravilo Avastin v kombinaciji s 5-fluorouracilom oziroma folinsko kislino.

This was a phase III randomised, double-blind, active-controlled clinical trial evaluating Avastin in combination with IFL as first-line treatment for metastatic carcinoma of the colon or rectum.
To je bilo randomizirano, dvojno slepo, aktivno kontrolirano klinično preskušanje faze III, ki je proučevalo zdravilo Avastin v kombinaciji z IFL v prvi liniji zdravljenja metastatskega raka debelega črevesa in danke.

Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.
Bolniki, ki so v okviru adjuvantnega zdravljenja v zadnjih 12 mesecih prejeli sheme, ki so vsebovale taksan ali antraciklin, se ne smejo zdraviti z zdravilom Avastin v kombinaciji s kapecitabinom.

Two large Phase III trials were designed to investigate the treatment effect of Avastin in combination with two individual chemotherapy agents, as measured by the primary endpoint of PFS.
Za preučevanje učinka zdravljenja z zdravilom Avastin v kombinaciji z dvema posameznima kemoterapevtskima zdraviloma sta bili zasnovani dve veliki preskušanji faze III, v katerih je bil primarni cilj preživetje brez napredovanja bolezni(PFS, progressionfree survival).

Patients who have received taxane and anthracycline-containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.
Bolnike, ki so v obdobju 12 mesecev prejemali zdravljenje, ki vsebuje zdravljenje s taksanom in antraciklinom v dodatku, je treba izključiti iz zdravljenja z zdravilom Avastin v kombinaciji s kapecitabinom.

The incidence of venous thromboembolic events in clinical trials was similar in patients receiving Avastin in combination with chemotherapy compared to those receiving the control chemotherapy alone.
Venska trombembolija Incidenca venskih trombemboličnih dogodkov v kliničnih preskušanjih je bila pri bolnikih, ki so prejemali zdravilo Avastin v kombinaciji s kemoterapijo in bolnikih v kontrolni skupini, ki so prejemali le kemoterapijo, podobna.

Arterial Thromboembolism(see section 4.8) In five randomised clinical trials, the incidence of arterial thromboembolic events including cerebrovascular accidents(CVAs), transient ischaemic attacks(TIAs) and myocardial infarctions(MIs) was higher in patients receiving Avastin in combination with chemotherapy compared to those who received chemotherapy alone.
Arterijska trombembolija(glejte poglavje 4. 8) V petih randomiziranih kliničnih preskušanjih je bila incidenca dogodkov arterijske trombembolije, vključno s cerebrovaskularnimi dogodki, tranzitornimi ishemičnimi atakami(TIA) in miokardnimi infarkti, večja pri bolnikih, ki so prejemali zdravilo Avastin v kombinaciji s kemoterapijo v primerjavi s tistimi, ki so prejemali le kemoterapijo.

Study E2100 was an open-label, randomised, active controlled, multicentre clinical trial evaluating Avastin in combination with paclitaxel for locally recurrent or metastatic breast cancer in patients who had not previously received chemotherapy for locally recurrent and metastatic disease.
Študija E2100 je bilo odprto, randomizirano, aktivno kontrolirano multicentrično klinično preskušanje, ki je proučevalo zdravilo Avastin v kombinaciji s paklitakselom pri bolnikih z lokalno ponovitvijo ali razsojem raka dojk, ki predhodno niso prejeli kemoterapije za lokalno recidivno ali metastatsko bolezen.

The overall safety profile of Avastin is based on data from over 3,500 patients with various malignancies, predominantly treated with Avastin in combination with chemotherapy in clinical trials.
Celotni varnostni profil zdravila Avastin temelji na podatkih več kot 3500 bolnikov z različnimi malignimi boleznimi, ki so se v kliničnih preskušanjih večinoma zdravili z zdravilom Avastin v kombinaciji s kemoterapijo.

In study JO25567, all grade hypertension was observed in 77.3% of the patients who received Avastin in combination with erlotinib as first-line treatment for non-squamous NSCLC with EGFR activating mutations, compared to 14.3% of patients treated with erlotinib alone.
V študiji JO25567 so hipertenzijo vseh stopenj opazili pri 77,3% bolnikov, ki so prejemali zdravilo Avastin v kombinaciji z erlotinibom v prvi liniji zdravljenja neskvamoznega nedrobnoceličnega raka pljuč z EGFR-aktivirajočimi mutacijami, v primerjavi s 14,3% bolnikov, zdravljenih samo z erlotinibom.

In clinical trials, the incidence of arterial thromboembolic reactions including cerebrovascular accidents(CVAs), transient ischaemic attacks(TIAs) and myocardial infarctions(MIs) was higher in patients receiving Avastin in combination with chemotherapy compared to those who received chemotherapy alone.
V kliničnih preskušanjih je bila incidenca arterijskih trombemboličnih neželenih učinkov, vključno s cerebrovaskularnimi neželenimi učinki, tranzitornimi ishemičnimi atakami(TIA) in miokardnimi infarkti, večja pri bolnikih, ki so prejemali zdravilo Avastin v kombinaciji s kemoterapijo v primerjavi s tistimi, ki so prejemali le kemoterapijo.

This was a phase III randomised double-blind trial conducted to evaluate the efficacy and safety of Avastin in combination with interferon(IFN) alfa-2a versus IFN alfa-2a alone as first-line treatment in mRCC.
Učinkovitost in varnost zdravila Avastin v kombinaciji z interferonom alfa-2a v primerjavi s samim interferonom alfa-2a v prvi liniji zdravljenja metastatskega raka ledvičnih celic sta bili ovrednoteni v randomiziranem, dvojno slepem kliničnem preskušanju faze III.

This was a randomised, double-blind, phase II clinical trial investigating Avastin 10 mg/kg in a 2 weekly schedule with the same dose of Avastin in combination with 150 mg daily erlotinib, in patients with metastatic clear cell RCC.
To je bilo randomizirano, dvojno slepo klinično preskušanje faze II, ki je pri bolnikih z metastatskim svetloceličnim karcinomom ledvičnih celic proučevalo zdravilo Avastin, dajano v odmerku 10 mg/kg v dvotedenski shemi, in enak odmerek zdravila Avastin v kombinaciji s 150 mg erlotiniba na dan.

This was a phase II randomised, double-blind, active-controlled clinical trial evaluating the efficacy and safety of Avastin in combination with 5-FU/ FA as first-line treatment for metastatic colorectal cancer in patients who were not optimal candidates for first-line irinotecan treatment.
To je bilo randomizirano, aktivno kontrolirano, dvojno slepo klinično preskušanje faze II, v katerem so proučevali učinkovitost in varnost zdravila Avastin v kombinaciji s kemoterapevtsko shemo 5- FU/ FA v prvi liniji zdravljenja bolnikov z metastatskim rakom debelega črevesa in danke, ki niso bili najprimernejši kandidati za prvo linijo zdravljenja z irinotekanom.

In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that Avastin in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone.
V tem preskušanju sta bila primarna cilja dva: pokazati, da je shema XELOX neinferiorna shemi FOLFOX-4, in da je zdravilo Avastin v kombinaciji s kemoterapevtskima shemama FOLFOX-4 ali XELOX superiorno samostojni kemoterapiji.

Cerebrovascular accidents(including transient ischaemic attacks) were reported in up to 2.7% of patients treated with Avastin in combination with chemotherapy compared to up to 0.5% of patients treated with chemotherapy alone.
O cerebrovaskularnih dogodkih(vključno s tranzitornimi ishemičnimi atakami) so poročali pri do 2,7% bolnikov, ki so jih zdravili z zdravilom Avastin v kombinaciji s kemoterapijo v primerjavi z do 0,5% bolnikov, ki so bili zdravljeni le s kemoterapijo.

There were neither statistically significant nor clinically relevant differences in bevacizumab clearance in patients receiving Avastin monotherapy compared to patients receiving Avastin in combination with interferon alfa-2a, erlotinib or chemotherapies(IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine, doxorubicin or cisplatin/gemcitabine).
Ki so prejemali samostojno zdravljenje z zdravilom Avastin, v primerjavi z bolniki, ki so prejemali zdravilo Avastin v kombinaciji z interferonom alfa-2a, erlotinibom ali kemoterapijami(IFL, 5-FU/LV, karboplatin/paklitaksel, kapecitabin, doksorubicin ali cisplatin/gemcitabin), ni bilo statistično značilnih ali klinično pomembnih razlik v očistku bevacizumaba.